Heteroaromatic analogs of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2- [bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909) as high-affinity dopamine reuptake inhibitors

Journal of Medicinal Chemistry

Volumn 40, Issue 5, 1997, Pages 705-716

  Matecka, Dorota ^a   Lewis, David ^a   Rothman, Richard B ^b   Dersch, Christina M ^b   Wojnicki, Francis H E ^a   Glowa, John R ^a   DeVries, A Courtney ^c   Pert, Agu ^c   Rice, Kenner C ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLALLYL)PIPERAZINE; 1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLPROPYL)PIPERAZINE; 1 [2 [BIS(4 FLUOROPHENYL)METHOXY]ETHYL] 4 (3 PHENYLALLYL)PIPERAZINE DIMESILATE; COCAINE; DOPAMINE UPTAKE INHIBITOR; VANOXERINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG EFFECT; DRUG POTENCY; DRUG SELECTIVITY; FOOD INTAKE; INTRAVENOUS DRUG ADMINISTRATION; LIGAND BINDING; LOCOMOTION; MONKEY; NONHUMAN; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANIMALS; CARRIER PROTEINS; COCAINE; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; FEEDING BEHAVIOR; LIGANDS; MACACA MULATTA; MAGNETIC RESONANCE SPECTROSCOPY; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MOLECULAR STRUCTURE; MOTOR ACTIVITY; NERVE TISSUE PROTEINS; PENTAZOCINE; PIPERAZINES; RATS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0031055081     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9606599     Document Type: Article

References (45)

1. McCoy, C. B.; Inciardi, J. A. Sex, Drugs, and the Continuing Spread of AIDS; Roxbury Publishing Co.: Los Angeles, CA, 1995.
2. McCoy, C. B.; Metsch, L. R.; Inciardi, J. A.; Anwyl, R. S.; Wingerd, J.; Bletzer, K. Sex, Drugs, and the Spread of HIV/AIDS in Belle Glade, Florida. Med. Anthrop. Quart. 1996, 10, 83-93.
3. Johanson, C.-E.; Fischman, M. W. The Pharmacology of Cocaine Related to its Abuse. Pharmacol. Rev. 1989, 41, 3-52.
4. Carroll, F. I.; Lewin, A. H.; Boja, J. W.; Kuhar, M. J. Cocaine Receptor: Biochemical Characterization and Structure-Activity Relationship Studies of Cocaine Analogues at the Dopamine Transporter. J. Med. Chem. 1992, 35, 969-981.
5. Benowitz, N. L. Clinical Pharmacology and Toxicology of Cocaine. Pharmacol. Toxicol. 1993, 72, 3-12.
6. Kuhar, M. J. Molecular Pharmacology of Cocaine: a Dopamine Hypothesis and its Implications. In Cocaine: Scientific and social dimensions; Bock, G. R., Whelan, J., Eds.; John Wiley & Sons: New York, 1992; pp 81-95.
7. Ritz, M. C.; Lamb, R. J.; Goldberg, S. R.; Kuhar, M. J. Cocaine Receptors on Dopamine Transporters are Related to Self-administration of Cocaine. Science 1987, 237, 1219-1223.
8. Kuhar, M. J.; Ritz, M. C.; Boja, J. W. The Dopamine Hypothesis of the Reinforcing Properties of Cocaine. Trends Neurosci. 1991, 14, 299-302.
9. Wise, R. A. Catecholamine Theories of Reward: A Critical Review. Brain Res. 1978, 152, 215-247.
10. Rothman, B. R.; Mele, A.; Reid, A. A.; Akunne, H.; Greig, N.; Thurkauf, A.; Rice, K. C.; Pert, A. Tight Binding Dopamine Inhibitors as Cocaine Antagonists. A Strategy for Drug Development. FEBS Lett. 1989, 257, 341-344.
11. Rothman, R. B. High Affinity Dopamine Reuptake Inhibitors as Potential Cocaine Antagonists: A Strategy for Drug Development. Life Sci. 1990, 46, PL217-PL221.
12. Rothman, R. B.; Glowa, J. R. A Review of the Effects of Dopaminergic Agents on Humans, Animals, and Drug-Seeking Behavior, and its Implications for Medication Development. Focus on GBR 12909. Mol. Neurobiol. 1995, 10, 1-19.
13. Rothman, R. B. A Review of the Effects of Dopaminergic Agents in Humans: Implications for Medication Development. NIDA Res. Monogr. 1994, 145, 67-87.
14. Van der Zee, P.; Koger, H. S.; Goojtes, J.; Hespe, W. Aryl 1,4-Dialk(en)ylpiperazines as Selective and Very Potent Inhibitors of Dopamine Uptake. Eur. J. Med. Chem. 1980, 15, 363-370.
15. Andersen, P. H. The Dopamine Uptake Inhibitor GBR 12909: Selectivity and Molecular Mechanism of Action. Eur. J. Pharmacol. 1989, 166, 493-504.
16. 3H]GBR 12935 Binding In vitro to Rat Striatal Membranes: Labeling of the Dopamine Uptake Complex. J. Neurochem. 1987, 48, 1887-1896.
17. Rothman, R. B.; Grieg, N.; Kim, A.; de Costa, B. R.; Rice, K. C.; Carroll, F. I.; Pert, A. Cocaine and GBR 12909 Produce Equivalent Motoric Responses at Different Occupancy of the Dopamine Transporter. Pharmacol. Biochem. Behav. 1992, 43, 1135-1142.
18. Rothman, R. B.; Mele, A.; Reid, A. A.; Akunne, H. C.; Greig, N.; Thurkauf, A.; de Costa, B. R.; Rice, K. C.; Pert, A. GBR 12909 Antagonizes the Ability of Cocaine to Elevate Extracellular Levels of Dopamine. Pharmacol. Biochem. Behav. 1991, 40, 387-397.
19. Baumann, M. H.; Char, G. U.; de Costa, B. R.; Rice, K. C.; Rothman, R. B. GBR 12909 Attenuates Cocaine-Induced Activation of Mesolimbic Dopamine Neurons in the Rat. J. Pharmacol. Exp. Ther. 1994, 271, 1216-1222.
20. Glowa, J. R.; Wojnicki, F. H. E.; Matecka, D.; Bacher, J. D.; Mansbach, R. S.; Balster, R. L.; Rice, K. C. Effects of Dopamine Reuptake Inhibitors on Food- and Cocaine-Maintained Responding: I. Dependence on Unit Dose of Cocaine. Exp. Clin. Psychopharmacol. 1995, 3, 219-231.
21. Glowa, J. R.; Wojnicki, F. H. E.; Matecka, D.; Rice, K. C.; Rothman, R. B. Effects of Dopamine Reuptake Inhibitors on Food- and Cocaine-Maintained Responding: II. Comparisons with Other Drugs and Repeated Administrations. Exp. Clin. Psychopharmacol. 1995, 3, 232-239.
22. Sogaard, U.; Michalow, J.; Butler, B.; Laursen, A. L.; Ingersen, S. H.; Skrumsager, B. K.; Rafaelsen, O. J. A Tolerance Study of Single and Multiple Dosing of the Selective Dopamine Inhibitor GBR 12909 in Healthy Subjects. Int. Clin. Psychopharmacol. 1990, 5, 237-251.
23. Bonnet, J.-J.; Costentin, J. GBR 12783, a Potent and Selective Inhibitor of Dopamine Uptake: Biochemical Studies In vivo and Ex vivo. Eur. J. Pharmacol. 1986, 121, 199-209.
24. Heikkila, R. E.; Manzino, L. Behavioral Properties of GBR 12909, GBR 13096 and GBR 13098: Specific Inhibitors of Dopamine Uptake. Eur. J. Pharmacol. 1984, 103, 241-248.
25. Rothman, R. B.; Lewis, B.; Dersch, C. M.; Xu, H.; Radesca, L.; de Costa, B. R.; Rice, K. C.; Kilburn, R. B.; Akunne, H. C.; Pert, A. Identification of a GBR 12935 Homolog, LR 1111, Which is over 4,000-fold Selective for the Dopamine Transporter, Relative to Serotonin and Norepinephrine Transporters. Synapse 1993, 14, 34-39.
26. Matecka, D.; Radesca, L.; de Costa, B.; Rothman, R. B.; Dersch, C.; Akunne, H.; Lewis, B.; Partilla, J.; Xu, H.; Pert, A.; Rice, K. C. Synthesis, Receptor Binding and Behavioral Studies of N-(2-Diphenylmethoxyethyl)-N′-(3-phenylpropyl)homopiperazine, a Novel GBR 12935 Analog). NIDA Res. Monogr. 1993, 132, 381.
27. Matecka, D.; Rice, K. C.; Rothman, R. B.; de Costa, B. R.; Glowa, J. R.; Wojnicki, F. H.; Pert, A.; George, C.; Carroll, F. I.; Silverthorn, M. L.; Dersch, C. M.; Becketts, K. M.; Partilla, J. S. Synthesis and Absolute Configuration of Chiral Piperazines Related to GBR 12909 as Dopamine Reuptake Inhibitors. Med. Chem. Res. 1995, 5, 43-53.
28. Matecka, D.; Rothman, R. B.; Radesca, L.; de Costa, B. R.; Dersch, C. M.; Partilla, J. S.; Pert, A.; Glowa, J.; Wojnicki, F. H. E.; Rice, K. C. Development of Novel, Potent and Selective Dopamine Reuptake Inhibitors Through Alteration of the Piperazine Ring of 1-[(2-Diphenylmethoxy)ethyl]- and 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909). J. Med. Chem. 1996, 39, 4704-4716.
29. Deutsch, H. M.; Schweri, M. M.; Culbertson, C. T.; Zalkow, L. H. Synthesis and Pharmacology of Irreversible Affinity Labels as Potential Cocaine Antagonists: Aryl 1,4-Dialkylpiperazines Related to GBR 12783. Eur. J. Pharm. 1992, 220, 173-180.
30. Foulon, C.; Garreau, L.; Chalon, S.; Desplanches, G.; Frangin, Y.; Besnard, J.-C.; Baulieu, J. L.; Guilloteau, D. Synthesis and In vitro Binding Properties of Halogenated Analogues of GBR as New Dopamine Uptake Carrier Ligands. Nucl. Med. Biol. 1992, 19, 597-600.
31. Bagley, J. R.; Wynn, R. L.; Rudo, F. G.; Doorley, B. M.; Spencer, K. H.; Spaulding, T. New 4-(Heteroanilido)piperidines, Structurally Related to the Pure Opioid Agonist Fentanyl, with Agonist and/or Antagonist Properties. J. Med. Chem. 1989, 32, 663-671.
32. Bagley, J. R.; Kudzma, L. V.; Lalinde, N. L.; Colapret, J. A.; Huang, B.-S.; Lin, B.-S.; Jerussi, T. P.; Benvega, M. J.; Doorley, B. M.; Ossipov, M. H.; Spaulding, T. C.; Spencer, H. K. Evolution of the 4-Anilidopiperidine Class of Opioid Analgesics. Med. Res. Rev. 1991, 11, 403-436.
33. Matecka, D.; de Costa, B. R.; Rothman, R. B.; Dersch, C.; Partilla, J.; Silverthorn, M. L.; Pert, A.; Glowa, J.; Wojnicki, F.; Jacobson, A.; Rice, K. C. Further Investigation of Structure-Activity Relationship of New GBR 12935 and GBR 12909 Analogs as Potent Dopamine Reuptake Inhibitors. NIDA Res. Monogr. 1995, 153, 361.
34. Matecka, D.; Lewis, D.; Rothman, R. B.; Marschke, C. K.; Dersch, C. M.; Partilla, J. S.; Pert, A.; Glowa, J. R.; Wojnicki, F. H. E.; Jacobson, A. E.; Rice, K. C. Heterocyclic GBR 12909 Analogs as Potential Cocaine Abuse Treatment Agents. NIDA Res. Monogr. 1996, 162, 228.
35. Yoon, N. M.; Brown, H. C. Selective Reductions. XII. Explorations in Some Representative Applications of Aluminum Hydride for Selective Reductions. J. Am. Chem. Soc. 1968, 90, 2927-2938.
36. Coderc, E.; Martin-Fardon, R.; Vignon, J.; Kamenka, J. M. New Compounds Resulting From Structural and Biochemical Similarities Between GBR 12783 and BTCP, Two Potent Inhibitors of Dopamine Uptake. Eur. J. Med. Chem. 1993, 28, 893-898.
37. 3H]DA-Uptake-Inhibition to Transporter-Binding-Inhibition Ratios for the In vitro Evaluation of Putative Cocaine Antagonists. Life Sci. 1993, 53, PL267-PL272.
38. 125I]RTI-55. J. Pharmacol. Exp. Ther. 1994, 270, 296-309.
39. 3H](+)-Pentazocine: A Potent and Highly Selective Benzomorphan-Based Probe for Sigma-1 Receptors. Mol. Neuropharmacol. 1993, 3, 117-126.
40. 3H]1,3-Di(2-tolyl)-guanidine of Two High Affinity Binding Sites in Guinea Pig Brain: Evidence for Allosteric Regulation by Calcium Channel Antagonists and Pseudoallosteric Modulation by σ Ligands. Mol. Pharmacol. 1991, 39, 222-232.
41. Rodbard, D.; Lenox, R. H.; Wray, H. L.; Ramseth, D. Statistical Characterization of the Random Errors in the Radioimmunoassay Dose-Response Variable. Clin. Chem. 1976, 22, 350-358.
42. Knott, G. D.; Reece, D. K. MLAB: A Civilized Curve Fitting System. Online 1972 International Conference, 1972.
43. 3H]BTCP in Rat Caudate Membranes. J. Pharmacol. Exp. Ther. 1994, 268, 1462-1475.
44. 3H]-(+)-Pentazocine in Guinea Pig Brain. NIDA Res. Monogr. 1993, 132, 404.
45. Wojnicki, F. H. E.; Bacher, J. D.; Glowa, J. R. The Use of Subcutaneous Vascular Access Ports in Rhesus Monkeys. Lab. Anim. Med. 1994, 44, 491-494.